Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis

Abstract Background and Aim Molecular‐targeted agents such as lenvatinib and sorafenib have been approved to treat hepatocellular carcinoma (HCC). However, the choice between these two agents in the primary treatment for advanced HCC is still under debate with conflicting results. We sought to evalu...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Vikash Jaiswal, Maha Hameed, Sidra Naz, Poulami Roy, Novonil Deb, Janta Ukrani, Gautham Varun Krishna Mohan, Amira M Taha, Helen Huang, Vikash Kumar, Bhavyakumar Vachhani, Abdelrahman M Attia, Supti D Nath, Mostafa A Solimn, Dattatreya Mukherjee
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2023-12-01
Serie:	JGH Open
Soggetti:	hepatocellular carcinoma lenvatinib mortality sorafenib
Accesso online:	https://doi.org/10.1002/jgh3.12999
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!